The cholinergic system in subtypes of Alzheimer’s disease: an in vivo longitudinal MRI study

[1]  J. Cummings,et al.  Repurposed agents in the Alzheimer’s disease drug development pipeline , 2020, Alzheimer's Research & Therapy.

[2]  Eric Westman,et al.  Biological subtypes of Alzheimer disease , 2020, Neurology.

[3]  Daniel Ferreira,et al.  Cholinergic white matter pathways make a stronger contribution to attention and memory in normal aging than cerebrovascular health and nucleus basalis of Meynert , 2020, NeuroImage.

[4]  E. Westman,et al.  Subtypes of Alzheimer's Disease Display Distinct Network Abnormalities Extending Beyond Their Pattern of Brain Atrophy , 2019, Front. Neurol..

[5]  M. Eriksdotter,et al.  Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF , 2019, Front. Neurosci..

[6]  Lena Cavallin,et al.  A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium , 2018, Alzheimer's & Dementia.

[7]  Stefan Teipel,et al.  The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles , 2018, Human brain mapping.

[8]  Lena Cavallin,et al.  The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkers , 2018, Neurobiology of Aging.

[9]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2018 , 2018, Alzheimer's & dementia.

[10]  G. Fink,et al.  Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease , 2018, Brain : a journal of neurology.

[11]  Magda Tsolaki,et al.  Heterogeneous patterns of brain atrophy in Alzheimer's disease , 2018, Neurobiology of Aging.

[12]  Lena Cavallin,et al.  Distinct subtypes of Alzheimer’s disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications , 2017, Scientific Reports.

[13]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[14]  J. Trojanowski,et al.  Heterogeneity of neuroanatomical patterns in prodromal Alzheimer’s disease: links to cognition, progression and biomarkers , 2016, Brain : a journal of neurology.

[15]  Sterling C. Johnson,et al.  Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology , 2016, Nature Communications.

[16]  Magda Tsolaki,et al.  Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition , 2016, European Radiology.

[17]  Eric Westman,et al.  Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device , 2016, Alzheimer's Research & Therapy.

[18]  L. Grinberg,et al.  Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment. , 2016, Cerebral cortex.

[19]  Bilwaj Gaonkar,et al.  CHIMERA: Clustering of Heterogeneous Disease Effects via Distribution Matching of Imaging Patterns , 2016, IEEE Transactions on Medical Imaging.

[20]  Dong Young Lee,et al.  Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer’s Disease , 2015, PloS one.

[21]  Eric Westman,et al.  Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease , 2015, Alzheimer's & Dementia.

[22]  H. Braak,et al.  The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. , 2015, Brain : a journal of neurology.

[23]  A. Simmons,et al.  Practical cut‐offs for visual rating scales of medial temporal, frontal and posterior atrophy in Alzheimer's disease and mild cognitive impairment , 2015, Journal of internal medicine.

[24]  K. Zilles,et al.  Deep Brain Stimulation of the Nucleus Basalis of Meynert in Early Stage of Alzheimer's Dementia , 2015, Brain Stimulation.

[25]  H. Gertz,et al.  Early neurone loss in Alzheimer’s disease: cortical or subcortical? , 2015, Acta neuropathologica communications.

[26]  Andrew Simmons,et al.  Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor. , 2014, Journal of Alzheimer's disease : JAD.

[27]  Stefan J. Teipel,et al.  Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects , 2014, Alzheimer's & Dementia.

[28]  S. Pluchino,et al.  Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. , 2014, Journal of molecular cell biology.

[29]  M. Mesulam,et al.  Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease , 2013, The Journal of comparative neurology.

[30]  L. Maffei,et al.  Environmental enrichment strengthens corticocortical interactions and reduces amyloid-β oligomers in aged mice , 2013, Front. Aging Neurosci..

[31]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[32]  Michael Söderman,et al.  Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. , 2012, Journal of neurosurgery.

[33]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  Ove Almkvist,et al.  Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[35]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[36]  W. M. van der Flier,et al.  Visual assessment of posterior atrophy development of a MRI rating scale , 2011, European Radiology.

[37]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[38]  K. Amunts,et al.  Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. , 2010, Cerebral cortex.

[39]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[40]  Mollie E. Brooks,et al.  Generalized linear mixed models: a practical guide for ecology and evolution. , 2009, Trends in ecology & evolution.

[41]  E. Mufson,et al.  Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications , 2008, Expert review of neurotherapeutics.

[42]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[43]  John Ashburner,et al.  A fast diffeomorphic image registration algorithm , 2007, NeuroImage.

[44]  L. Thal,et al.  Nerve growth factor promotes survival of new neurons in the adult hippocampus , 2007, Neurobiology of Disease.

[45]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[46]  Steven G Potkin,et al.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.

[47]  P. Connelly,et al.  Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[48]  K. Allendoerfer,et al.  Cooperative Effects of Sonic Hedgehog and NGF on Basal Forebrain Cholinergic Neurons , 2002, Molecular and Cellular Neuroscience.

[49]  Murat Emre,et al.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study , 2000, The Lancet.

[50]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[51]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[52]  A. Levey,et al.  Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey , 1983, The Journal of comparative neurology.

[53]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[54]  Stefan Klöppel,et al.  Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study. , 2014, Journal of Alzheimer's disease : JAD.

[55]  # The Author(s) 2011. This article is published with open access at Springerlink.com , 2010 .

[56]  M. Mesulam,et al.  The cholinergic innervation of the human cerebral cortex. , 2004, Progress in brain research.

[57]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..